🇺🇸 FDA
Patent

US 7470431

Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer

granted A61KA61K38/164A61K38/4886

Quick answer

US patent 7470431 (Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer) held by The Regents of the University of Colorado expires Mon Dec 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado
Grant date
Tue Dec 30 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K38/164, A61K38/4886, A61K38/4893